Amino-bisphosphonates in heterotopic ossification: First experience in five consecutive cases

Spinal Cord

Volumn 43, Issue 10, 2005, Pages 604-610

  Schuetz, P ^a   Mueller, B ^a   Christ Crain, M ^a   Dick, W ^a   Haas, H ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Amino bisphosphonate; Established ossification; Excision surgery; Heterotopic ossification (HO); High risk patients; Observational study; Pamidronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEVER; GASTROINTESTINAL TOXICITY; HETEROTOPIC OSSIFICATION; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; MALE; NEPHROTOXICITY; OSTEOMALACIA; OSTEOPOROSIS; PRIORITY JOURNAL; RADIOGRAPHY; RETROSPECTIVE STUDY; SPINAL CORD INJURY; UNIVERSITY HOSPITAL;

AGED; ANTI-INFLAMMATORY AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OBSERVATION; OSSIFICATION, HETEROTOPIC; RETROSPECTIVE STUDIES; SPINAL CORD INJURIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 25844439905     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sj.sc.3101761     Document Type: Article

References (66)

1. van Kuijk AA, Geurts AC, van Kuppevelt HJ. Neurogenic heterotopic ossification in spinal cord injury. Spinal Cord 2002; 40: 313-326.
2. Rosendahl S, Christoffersen JK, Norgaard M. Para-articular ossification following hip replacement. 70 arthroplasties ad modum Moore using McFarland's approach. Acta Orthop Scand 1977; 48: 400-404.
3. Lazansky MG. Complications revisited. The debit side of total hip replacement. Clin Orthop 1973; 95: 96-103.
4. Ahrengart L. Periarticular heterotopic ossification after total hip arthroplasty. Risk factors and consequences. Clin Orthop 1991; 263: 49-58.
5. Neal B, Gray H, MacMahon S, Dunn L. Incidence of heterotopic bone formation after major hip surgery. ANZ J Surg 2002; 72: 808-821.
6. Kaplan FS, Shore EM. Progressive osseous heteroplasia. J Bone Miner Res 2000; 15: 2084-2094.
7. Shore EM, Glaser DL, Gannon FH. Osteogenic induction in hereditary disorders of heterotopic ossification. Clin Orthop 2000; 374: 303-316.
8. Shore EM et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002; 346: 99-106.
9. Kaplan FS, McCluskey W, Hahn G, Tabas JA, Muenke M, Zasloff MA. Genetic transmission of fibrodysplasia ossificans progressiva. Report of a family. J Bone Joint Surg Am 1993; 75: 1214-1220.
10. Feldman G et al. Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31. Am J Hum Genet 2000; 66: 128-135.
11. Urist MR, DeLange RJ, Finerman GA. Bone cell differentiation and growth factors. Science 1983; 220: 680-686.
12. Olmsted EA, Kaplan FS, Shore EM. Bone morphogenetic protein-4 regulation in fibrodysplasia ossificans progressiva. Clin Orthop 2003; 408: 331-343.
13. Kaplan FS, Glaser DL, Hebela N, Shore EM. Heterotopic ossification. J Am Acad Orthop Surg 2004; 12: 116-125.
14. Thomas BJ, Amstutz HC. Prevention of heterotopic bone formation: clinical experience with diphosphonates. Hip 1987; 59-69.
15. Shehab D, Elgazzar AH, Collier BD. Heterotopic ossification. J Nucl Med 2002; 43: 346-353.
16. Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med 1985; 26: 125-132.
17. Smith R. Fibrodysplasia (myositis) ossificans progressiva. Clinical lessons from a rare disease. Clin Orthop 1998; 346: 7-14.
18. Neal B. Effects of heterotopic bone formation on outcome after hip arthroplasty. ANZ J Surg 2003; 73: 422-426.
19. Wilkinson JM, Stockley I, Hamer AJ, Barrington NA, Eastell R. Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty. J Orthop Res 2003; 21: 529-534.
20. Banovac K, Gonzalez F. Evaluation and management of heterotopic ossification in patients with spinal cord injury. Spinal Cord 1997; 35: 158-162.
21. Kaplan FS, Strear CM, Zasloff MA. Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin Orthop 1994; 304: 238-247.
22. Johnson EE, Kay RM, Dorey FJ. Heterotopic ossification prophylaxis following operative treatment of acetabular fracture. Clin Orthop 1994; 305: 88-95.
23. Kolbl O, Knelles D, Barthel T, Raunecker F, Flentje M, Eulert J. Preoperative irradiation versus the use of nonsteroidal anti-inflammatory drugs for prevention of heterotopic ossification following total hip replacement: the results of a randomized trial. Int J Radiat Oncol Biol Phys 1998; 42: 397-401.
24. Neal BC et al. A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop Scand 2000; 71: 122-128.
25. Neal B, Rodgers A, Dunn L, Fransen M. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 2000; 3: CD001160.
26. Kienapfel H et al. Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. Arch Orthop Trauma Surg 1999; 119: 296-302.
27. Iorio R, Healy WL. Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment. J Am Acad Orthop Surg 2002; 10: 409-416.
28. Ashton LA, Bruce W, Goldberg J, Walsh W. Prevention of heterotopic bone formation in high risk patients post-total hip arthroplasty. J Orthop Surg (Hong Kong) 2000; 8: 53-57.
29. Ahrengart L, Lindgren U. Heterotopic bone after hip arthroplasty. Defining the patient at risk. Clin Orthop 1993; 293: 153-159.
30. Garland DE, Orwin JF. Resection of heterotopic ossification in patients with spinal cord injuries. Clin Orthop 1989; 242: 169-176.
31. Stover SL, Niemann KM, Tulloss JR. Experience with surgical resection of heterotopic bone in spinal cord injury patients. Clin Orthop 1991; 263: 71-77.
32. Evarts CM, Ayers DC, Puzas JE. Prevention of heterotopic bone formation in high-risk patients by postoperative irradiation. Hip 1987; 70-83.
33. Moritomo H, Tada K, Yoshida T. Early, wide excision of heterotopic ossification in the medial elbow. J Shoulder Elbow Surg 2001; 10: 164-168.
34. Seegenschmiedt MH et al. Prevention of heterotopic ossification about the hip: final results of two randomized trials in 410 patients using either preoperative or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1997; 39: 161-171.
35. Thomas BJ, Amstutz HC. Results of the administration of diphosphonate for the prevention of heterotopic ossification after total hip arthroplasty. J Bone Joint Surg Am 1985; 67: 400-403.
36. Banovac K. The effect of etidronate on late development of heterotopic ossification after spinal cord injury. J Spinal Cord Med 2000; 23: 40-44.
37. Garland DE. Surgical approaches for resection of heterotopic ossification in traumatic brain-injured adults. Clin Orthop 1991; 263: 59-70.
38. Thomas BJ. Heterotopic bone formation after total hip arthroplasty. Orthop Clin North Am 1992; 23: 347-358.
39. Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 2004; 43: 658-661.
40. Marshall H, Bromilow J, Thomas AL, Arden NK. Pamidronate: a novel treatment for the SAPHO syndrome? Rheumatology (Oxford) 2002; 41: 231-233.
41. Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 1995; 12: 916-922.
42. Singh R, Menon Y, Cuchacovich R, Espinoza LR. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis: comment on the article by Maksymowych et al. Arthritis Rheum 2003; 48: 583-584; author reply 584.
43. Robinson JN, Sandom J, Chapman PT. Efficacy of pamidronate in complex regional pain syndrome type I. Pain Med 2004; 5: 276-280.
44. Hamida KS et al. Myositis ossificans circumscripta of the knee improved by alendronate. Joint Bone Spine 2004; 71: 144-146.
45. Brooker AF, Bowerman JW, Robinson RA, Riley Jr LH. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 1973; 55: 1629-1632.
46. Hu HP, Kuijpers W, Slooff TJ, van Horn JR, Versleyen DH. The effect of biphosphonate on induced heterotopic bone. Clin Orthop 1991; 272: 259-267.
47. Illingworth RS. Myositis ossificans progressiva (Munchmeyer's disease). Brief review with report of two cases treated with corticosteroids and observed for 16 years. Arch Dis Child 1971; 46: 264-268.
48. Brantus JF, Meunier PJ. Effects of intravenous etidronate and oral corticosteroids in fibrodysplasia ossificans progressiva. Clin Orthop 1998; 346: 117-120.
49. DeLee J, Ferrari A, Charnley J. Ectopic bone formation following low friction arthroplasty of the hip. Clin Orthop 1976; 121: 53-59.
50. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9: 2643-2658.
51. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106.
52. Francis MD, Flora L, King WR. The effects of disodium ethane-1-hydroxy-1, 1-diphosphonate on adjuvant induced arthritis in rats. Calcif Tissue Res 1972; 9: 109-121.
53. Garland DE, Alday B, Venos KG, Vogt JC. Diphosphonate treatment for heterotopic ossification in spinal cord injury patients. Clin Orthop 1983; 176: 197-200.
54. Finerman GA, Stover SL. Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDP. Metab Bone Dis Relat Res 1981; 3: 337-342.
55. Stover SL, Niemann KM, Miller III JM. Disodium etidronate in the prevention of postoperative recurrence of heterotopic ossification in spinal-cord injury patients. J Bone Joint Surg Am 1976; 58: 683-688.
56. Spielman G, Gennarelli TA, Rogers CR. Disodium etidronate: its role in preventing heterotopic ossification in severe head injury. Arch Phys Med Rehabil 1983; 64: 539-542.
57. Yutani Y, Ohashi H, Nishimura N, Yamano Y. Clinical effect of etidronate disodium (EHDP) on heterotopic ossification following total hip arthroplasty. Osaka City Med J 1995; 41: 63-73.
58. Meunier P, Chapuy MC, Courpron P, Vignon E, Edouard C, Bernard J. Clinical, biological and histological effects of ethane-1-hydroxy 1, 1-diphosphonate (EDHP) in Paget's disease. Rev Rhum Mal Osteoartic 1975; 42: 699-705.
59. Tucci JR, Bontha S. Intravenously administered pamidronate in the treatment of Paget's disease of bone. Endocr Pract 2001; 7: 423-429.
60. Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int 2004; 75: 189-196.
61. Jude EB et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001; 44: 2032-2037.
62. Anderson JJ, Woelffer KE, Holtzman JJ, Jacobs AM. Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg 2004; 43: 285-289.
63. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996; 14: 158-170.
64. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349: 457-463.
65. Parisi MS, Oliveri B, Mautalen CA. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone 2003; 33: 582-588.
66. Shapiro JR et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 2003; 72: 103-112.